Increased Warning About The Risk Of Suicidal Thoughts And Behaviors Being Added To Attention Deficit Hyperactivity Disorder (ADHD) Drug Labels
SUMMARY: On March 30, 2015 Health Canada issued an Information Update document with new safety information about Adderall, Concerta, Ritalin, and similar medications titled “ADHD drugs may increase risk of suicidal thoughts and behaviors in some people; benefits still outweigh risks”.
The following is a list of some brand name ADHD drugs to which this warning about suicide-related events in patients applies:
• Adderall XR (mixed salts amphetamine extended-release)
• Biphentin (methylphenidate controlled release)
• Concerta (methylphenidate extended release)
• Dexedrine (dextroamphetamine sulfate)
• Intuniv XR (guanfacine extended release)
• Ritalin (methylphenidate)
• Ritalin SR (methylphenidate extended release)
• Strattera (atomoxetine) [the warning was added to this drug label back in 2005]
• Vyvanse (lisdexamfetamine dimesylate)
We will continue to monitor the benefit – risk profile of these ADHD drugs as well as watch for any corresponding regulatory action by the FDA here in the US.
[Read this article in full at original source]